Ver­tex backs out of agree­ment with CRISPR Ther­a­peu­tics for stem cell ther­a­py can­di­date in di­a­betes

Ver­tex Phar­ma­ceu­ti­cals’ sub­sidiary Vi­a­Cyte is back­ing out of one of its col­lab­o­ra­tions with CRISPR Ther­a­peu­tics on gene-edit­ed stem cell ther­a­pies for di­a­betes.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.